7-Deaza-2'-C-methyladenosine - CAS 443642-29-3
Catalog number: 443642-29-3
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C12H16N4O4
Molecular Weight:
280.29
COA:
Inquire
Targets:
Others
Description:
7-Deaza-2’-C-methyladenosine is a hepatitis C virus (HCV) polymerase inhibitor.
Purity:
≥98%
Appearance:
White Solid
Synonyms:
7-Deaza-2'-C-methyl-D-adenosine (2R,​3R,​4R,​5R)​-​2-​(4-​Amino-​7H-​pyrrolo[2,​3-​d]​pyrimidin-​7-​yl)​-​5-​(hydroxymethyl)​-​3-​methyltetrahydrofura​n-​3,​4-​diol
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
Hepatitis C virus (HCV) polymerase inhibitor.
Quality Standard:
Enterprise standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.
Quantity:
Milligrams-Grams
Melting Point:
222 °C
InChIKey:
IRZRJANZDIOOIF-GAJNKVMBSA-N
InChI:
1S/C12H16N4O4/c1-12(19)8(18)7(4-17)20-11(12)16-3-2-6-9(13)14-5-15-10(6)16/h2-3,5,7-8,11,17-19H,4H2,1H3,(H2,13,14,15)/t7-,8-,11-,12-/m1/s1
Canonical SMILES:
CC1(C(C(OC1N2C=CC3=C2N=CN=C3N)CO)O)O
1.Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range.
Sandhu P;Vogel JS;Rose MJ;Ubick EA;Brunner JE;Wallace MA;Adelsberger JK;Baker MP;Henderson PT;Pearson PG;Baillie TA Drug Metab Dispos. 2004 Nov;32(11):1254-9. Epub 2004 Jul 30.
The technique of accelerator mass spectrometry (AMS) was validated successfully and used to study the pharmacokinetics and disposition in dogs of a preclinical drug candidate (7-deaza-2'-C-methyl-adenosine; Compound A), after oral and intravenous administration. The primary objective of this study was to examine whether Compound A displayed linear kinetics across subpharmacological (microdose) and pharmacological dose ranges in an animal model, before initiation of a human microdose study. The AMS-derived disposition properties of Compound A were comparable to data obtained via conventional techniques such as liquid chromatography-tandem mass spectrometry and liquid scintillation counting analyses. Compound A displayed multiphasic kinetics and exhibited low plasma clearance (5.8 ml/min/kg), a long terminal elimination half-life (17.5 h), and high oral bioavailability (103%). Currently, there are no published comparisons of the kinetics of a pharmaceutical compound at pharmacological versus subpharmacological doses using microdosing strategies. The present study thus provides the first description of the full pharmacokinetic profile of a drug candidate assessed under these two dosing regimens.
2.Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C.
Mello C;Aguayo E;Rodriguez M;Lee G;Jordan R;Cihlar T;Birkus G Antimicrob Agents Chemother. 2014;58(3):1546-55. doi: 10.1128/AAC.01746-13. Epub 2013 Dec 23.
Human rhinovirus type C (HRV-C) is a newly discovered enterovirus species frequently associated with exacerbation of asthma and other acute respiratory conditions. Until recently, HRV-C could not be propagated in vitro, hampering in-depth characterization of the virus replication cycle and preventing efficient testing of antiviral agents. Herein we describe several subgenomic RNA replicon systems and a cell culture infectious model for HRV-C that can be used for antiviral screening. The replicon constructs consist of genome sequences from HRVc15, HRVc11, HRVc24, and HRVc25 strains, with the P1 capsid region replaced by a Renilla luciferase coding sequence. Following transfection of the replicon RNA into HeLa cells, the constructs produced time-dependent increases in luciferase signal that can be inhibited in a dose-dependent manner by known inhibitors of HRV replication, including the 3C protease inhibitor rupintrivir, the nucleoside analog inhibitor MK-0608, and the phosphatidylinositol 4-kinase IIIβ (PI4K-IIIβ) kinase inhibitor PIK93. Furthermore, with the exception of pleconaril and pirodavir, the other tested classes of HRV inhibitors blocked the replication of full-length HRVc15 and HRVc11 in human airway epithelial cells (HAEs) that were differentiated in the air-liquid interface, exhibiting antiviral activities similar to those observed with HRV-16.
3.Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees.
Carroll SS;Ludmerer S;Handt L;Koeplinger K;Zhang NR;Graham D;Davies ME;MacCoss M;Hazuda D;Olsen DB Antimicrob Agents Chemother. 2009 Mar;53(3):926-34. doi: 10.1128/AAC.01032-08. Epub 2008 Dec 15.
Hepatitis C virus (HCV) infects an estimated 170 million individuals worldwide and is associated with an increased incidence of liver fibrosis, cirrhosis, and hepatocellular carcinoma. Currently approved therapies to treat HCV infection consist of combinations of pegylated alpha interferon and ribavirin which result in a sustained viral response in 40 to 60% of patients. Efforts to develop improved therapies include the development of direct inhibitors of virally encoded enzymes such as the viral RNA-dependent RNA polymerase. A nucleoside analog, 2'-C-methyl-7-deaza-adenosine (MK-0608), has been shown to inhibit viral RNA replication in the subgenomic HCV genotype 1b replicon, with a 50% effective concentration (EC(50)) of 0.3 microM (EC(90) = 1.3 microM). To determine efficacy in vivo, MK-0608 was administered to HCV-infected chimpanzees, resulting in dose- and time-dependent decreases in plasma viral loads. In separate experiments, chimpanzees dosed for 7 days with MK-0608 at 0.2 and 2 mg per kg of body weight per day by intravenous administration experienced average reductions in viral load of 1.0 and >5 log(10) IU/ml, respectively. Two other HCV-infected chimpanzees received daily doses of 1 mg MK-0608 per kg via oral administration.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 452342-37-9 GW-6604

GW-6604
(CAS: 452342-37-9)

GW6604 is a potent and selective ALK-5 inhibitor with an IC(50) of 140 nM and in a cellular assay inhibited TGF-beta-induced transcription of PAI-1 (IC(50): 500...

CAS 95734-82-0 Nedaplatin

Nedaplatin
(CAS: 95734-82-0)

Nedaplatin is a derivative of cisplatin and DNA damage agent for tumor colony forming units with IC50 of 94 μM.

CAS 434-05-9 Methenolone acetate

Methenolone acetate
(CAS: 434-05-9)

Metenolone enanthate,is a dihydrotestosterone based anabolic steroid with weak androgenic properties.

CAS 125-52-0 Oxyphencyclimine hydrochloride

Oxyphencyclimine hydrochloride
(CAS: 125-52-0)

The hydrochloride salt form of Oxyphencyclimine which could influence the peripheral parasympathetic system and increase the stomach secretions.

CAS 501104-16-1 Lalistat 1

Lalistat 1
(CAS: 501104-16-1)

Lalistat 1 is a lysosomal acid lipase inhibitor with IC50 value of 68 nM. It can block LAL-mediated lipid hydrolysis of acetylated LDL and reduce efflux of chol...

CAS 4474-91-3 5-​L-​isoleucine-Angiotensin II

5-​L-​isoleucine-Angiotensin II
(CAS: 4474-91-3)

Angiotensin II is an endogenous potent vasoconstrictor peptide typically generated by the removal of two residues from angiotensin I by angiotensin-converting e...

Integrin Antagonist 1 hydrochloride
(CAS: 1629249-40-6)

Integrin Antagonist 1 hydrochloride, a naphthyridine derivative, is a small molecule antagonist of integrin αvβ6. In the Fluorescence Polarisation Assay: human ...

JTV 519 fumarate
(CAS: 1883549-36-7)

The fumarate salt form of JTV 519, which has been found to be a Ryanodine receptor (RyR) inhibitor and also could be a useful intermediate.

Chemical Structure

CAS 443642-29-3 7-Deaza-2'-C-methyladenosine

Quick Inquiry

Verification code

Featured Items